Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Study STML-901-0119 is a dose-escalation study evaluating multiple doses and schedules of
orally administered SL-901 in patients with Advanced Solid Tumors.